The global exosome diagnostics and therapeutics market, valued at US$33 million in 2023, stood at US$59 million in 2024 and is projected to advance at a resilient CAGR of 81.2% from 2024 to 2032, culminating in a forecasted valuation of US$6,848 million by the end of the period. However, the candidates for exosome-based therapeutics are expected to be launched in the market from 2029 onwards. Thus, exosome diagnostics and therapeutics market in terms of revenue was estimated to be worth $59 million in 2024 and is poised to reach $6,848 million by 2032, growing at a CAGR of 81.2% from 2024 to 2032.
The global Exosome Diagnostics and Therapeutics market is rapidly emerging as one of the most exciting frontiers in precision medicine, liquid biopsy, regenerative medicine, and targeted drug delivery. Exosomes—tiny extracellular vesicles secreted by cells—are revolutionizing how diseases such as cancer, neurological disorders, cardiovascular conditions, and inflammatory diseases are diagnosed and treated.
Driven by advances in nanotechnology, biomarker discovery, and personalized medicine, the market is witnessing strong investment activity and strategic collaborations worldwide. According to recent industry analyses, the exosome diagnostics and therapeutics market is projected to experience double-digit growth through 2035.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=224782498
Here’s a look at the top 10 companies leading innovation in the Exosome Diagnostics and Therapeutics landscape.
1. Thermo Fisher Scientific
Thermo Fisher Scientific
Thermo Fisher Scientific remains a dominant player in the exosome ecosystem with its extensive portfolio of instruments, reagents, isolation kits, and analytical technologies. The company supports both research and clinical applications, particularly in oncology and precision medicine.
Its strong global presence, large-scale R&D investments, and expansion into exosome-based drug delivery technologies continue to strengthen its leadership position in the market.
2. Bio-Techne Corporation
Bio-Techne Corporation
Bio-Techne gained major traction in the market through its acquisition of Exosome Diagnostics. The company is best known for the ExoDx Prostate Test, a non-invasive liquid biopsy solution that helps assess prostate cancer risk using urine-derived exosomal biomarkers.
The company also offers advanced exosome characterization tools and biomarker research platforms, positioning itself as a leader in clinical exosome diagnostics.
3. Exosome Diagnostics Inc.
Exosome Diagnostics
Exosome Diagnostics is one of the pioneers in exosome-based liquid biopsy technologies. The company focuses on developing non-invasive diagnostic tests that utilize RNA and protein biomarkers derived from exosomes.
Its innovative diagnostic platforms are helping clinicians improve early cancer detection and treatment monitoring while minimizing invasive procedures.
4. Evox Therapeutics
Evox Therapeutics
Evox Therapeutics specializes in engineering exosomes for targeted drug delivery. The company is developing exosome-based therapeutics designed to deliver biologics, nucleic acids, and gene-editing payloads across difficult biological barriers.
Its technology platform is particularly promising for neurological and rare disease treatments.
5. Capricor Therapeutics
Capricor Therapeutics
Capricor Therapeutics is advancing exosome-based regenerative medicine technologies for inflammatory and cardiovascular diseases. The company’s StealthX platform focuses on engineered exosomes capable of targeted therapeutic delivery.
Capricor continues to attract attention for its work in muscular dystrophy and cardiac regeneration.
6. Aethlon Medical
Aethlon Medical
Aethlon Medical develops therapeutic technologies focused on exosome biology and blood purification systems. The company is exploring exoso
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=224782498
